HC Wainwright Reaffirms Buy Rating for iTeos Therapeutics (NASDAQ:ITOS)

HC Wainwright reaffirmed their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS) in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a $46.00 price objective on the stock.

Several other equities analysts also recently issued reports on the company. Wedbush reiterated an “outperform” rating and issued a $25.00 price objective on shares of iTeos Therapeutics in a research report on Wednesday. Wells Fargo & Company cut their price objective on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research report on Thursday, December 19th.

iTeos Therapeutics Price Performance

iTeos Therapeutics stock opened at $7.09 on Thursday. The company has a market capitalization of $259.03 million, a PE ratio of -2.25 and a beta of 1.38. iTeos Therapeutics has a one year low of $6.67 and a one year high of $18.75. The business has a 50 day simple moving average of $7.53 and a 200 day simple moving average of $9.54.

iTeos Therapeutics (NASDAQ:ITOS) last posted its earnings results on Wednesday, March 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.14) by $0.13. Equities analysts anticipate that iTeos Therapeutics will post -3.49 earnings per share for the current fiscal year.

Hedge Funds Weigh In On iTeos Therapeutics

Several institutional investors have recently bought and sold shares of the business. BVF Inc. IL acquired a new stake in shares of iTeos Therapeutics in the 4th quarter valued at $17,856,000. JPMorgan Chase & Co. increased its stake in shares of iTeos Therapeutics by 342.7% in the 4th quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company’s stock valued at $15,888,000 after buying an additional 1,601,477 shares during the period. Boxer Capital Management LLC acquired a new stake in shares of iTeos Therapeutics in the 4th quarter valued at $7,272,000. Jacobs Levy Equity Management Inc. increased its stake in shares of iTeos Therapeutics by 347.9% in the 4th quarter. Jacobs Levy Equity Management Inc. now owns 922,134 shares of the company’s stock valued at $7,082,000 after buying an additional 716,271 shares during the period. Finally, Millennium Management LLC increased its stake in shares of iTeos Therapeutics by 1,008.8% in the 4th quarter. Millennium Management LLC now owns 411,072 shares of the company’s stock valued at $3,157,000 after buying an additional 373,999 shares during the period. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.